Search - tctmd.com

Displaying 641 - 660 of 2866

Sort: Relevancy | Date

Presentation TCT 2019

Industry View on Controlled Trials for Heart Failure and Shock Devices

Presenter: William Abraham

September 27, 2019

Presentation TCT 2019

Extreme Aortic Valve Complex Calcification Creating High Risk for TAVR Complications (Rupture or PVR): Case Presentation and Procedural Decision-Making

Presenter: Chiu Wong

September 27, 2019

Presentation TCT 2019

Noble: Extended Follow-Up and Substudies

Presenter: Evald Christiansen

September 27, 2019

Presentation TCT 2019

Critical Appraisal of Post-LAA Closure Pharmacology and Device-Related Thrombus

Presenter: Kishore Harjai

September 27, 2019

Debate: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients - Con: Beware of Ischemic Complications — Not Ready to Drop DAPT Yet!

Presentation TCT 2019

Con: Beware of Ischemic Complications — Not Ready to Drop DAPT Yet!

Presenter: Robert Byrne

September 27, 2019

Presentation TCT 2019

ARC Initiative for Heart Failure and Shock: HF ARC, Shock ARC, and More

Presenter: Christopher O'Connor

September 27, 2019

Presentation TCT 2019

TAVR and Concomitant Atrial Fibrillation: Case Presentation

Presenter: Fabian Nietlispach

September 27, 2019

Debate: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients - Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presentation TCT 2019

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presenter: C. Michael Gibson

September 27, 2019

Presentation TCT 2019

Long-Term Safety of Drug-Coated Devices for Femoropopliteal Artery Revascularization: Updated Analysis of Medicare Beneficiary Data

Presenter: Eric Secemsky

September 27, 2019

Presentation TCT 2019

Excel: Extended Follow-Up and Most Important Substudies

Presenter: Ori Ben-Yehuda

September 27, 2019

Presentation TCT 2019

Devices for Heart Failure: FDA Perspectives on Trial Designs and Endpoints

Presenter: Bram Zuckerman

September 27, 2019

Presentation TCT 2019

Device-Related Thrombus: Mechanisms, Management, and Implications for Device Design

Presenter: Simon Cheung-chi Lam

September 27, 2019

Presentation TCT 2019

A Look Ahead for IVL

Presenter: Dean Kereiakes

September 27, 2019

Presentation TCT 2019

Update on Coronary IVL: Real-World Experiences

Presenter: Jonathan Hill

September 27, 2019

Presentation TCT 2019

The Forgotten Valve NO MORE! Perspectives from the Triluminate Experience in Severe Tricuspid Regurgitation

Presenter: Georg Nickenig

September 27, 2019

Presentation TCT 2019

Mitigating a Devastating Outcome: SENTINEL CPS in TAVR

Presenter: Kendra Grubb

September 27, 2019

Presentation TCT 2019

Clinical Context of SOLO and Future Results and Implications for Who to Treat

Presenter: Naomi Fisher

September 27, 2019

Presentation TCT 2019

Leave It to the Endocrinologist!

Presenter: Sonya Burgess

September 27, 2019

Presentation TCT 2019

No Access, No Problem

Presenter: Rajiv Tayal

September 27, 2019

Presentation TCT 2019

Real-World Experience of the LOTUS Edge Valve

Presenter: Hemal Gada

September 27, 2019

Advertisement

Industry View on Controlled Trials for Heart Failure and Shock Devices

Extreme Aortic Valve Complex Calcification Creating High Risk for TAVR Complications (Rupture or PVR): Case Presentation and Procedural Decision-Making

Noble: Extended Follow-Up and Substudies

Critical Appraisal of Post-LAA Closure Pharmacology and Device-Related Thrombus

Con: Beware of Ischemic Complications — Not Ready to Drop DAPT Yet!

ARC Initiative for Heart Failure and Shock: HF ARC, Shock ARC, and More

TAVR and Concomitant Atrial Fibrillation: Case Presentation

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Long-Term Safety of Drug-Coated Devices for Femoropopliteal Artery Revascularization: Updated Analysis of Medicare Beneficiary Data

Excel: Extended Follow-Up and Most Important Substudies

Devices for Heart Failure: FDA Perspectives on Trial Designs and Endpoints

Device-Related Thrombus: Mechanisms, Management, and Implications for Device Design

A Look Ahead for IVL

Update on Coronary IVL: Real-World Experiences

The Forgotten Valve NO MORE! Perspectives from the Triluminate Experience in Severe Tricuspid Regurgitation

Mitigating a Devastating Outcome: SENTINEL CPS in TAVR

Clinical Context of SOLO and Future Results and Implications for Who to Treat

Leave It to the Endocrinologist!

No Access, No Problem

Real-World Experience of the LOTUS Edge Valve

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content